1. Home
  2. LANV vs IPHA Comparison

LANV vs IPHA Comparison

Compare LANV & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lanvin Group Holdings Limited

LANV

Lanvin Group Holdings Limited

N/A

Current Price

$1.61

Market Cap

175.4M

Sector

Finance

ML Signal

N/A

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

HOLD

Current Price

$1.43

Market Cap

141.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LANV
IPHA
Founded
2015
1999
Country
China
France
Employees
N/A
163
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
175.4M
141.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
LANV
IPHA
Price
$1.61
$1.43
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$5.75
AVG Volume (30 Days)
20.0K
22.9K
Earning Date
04-30-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$180.36
Revenue Next Year
$3.33
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.03
$1.18
52 Week High
$2.69
$2.63

Technical Indicators

Market Signals
Indicator
LANV
IPHA
Relative Strength Index (RSI) 50.77 46.34
Support Level $1.39 $1.18
Resistance Level $1.86 $1.80
Average True Range (ATR) 0.16 0.08
MACD 0.02 0.02
Stochastic Oscillator 60.47 25.60

Price Performance

Historical Comparison
LANV
IPHA

About LANV Lanvin Group Holdings Limited

Lanvin Group Holdings Ltd engages in offering products ranging from apparel to leather goods, footwear, and accessories. The firm is operating mainly 5 portfolio brands, namely Lanvin, Wolford, Sergio Rossi, St. John, and Caruso. It derives the majority of its revenue from the Wolford segment.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: